^
Association details:
| Biomarker: | ERBB3 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | HMBD-501 (Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models
Published date:
04/04/2023
Excerpt:
In our preclinical studies, HMBD-501 demonstrates superior inhibition of tumor growth compared to other exatecan-based anti-HER3 ADCs, in a variety of in vitro and in vivo cancer models with a range of HER3 expression….Our findings strongly support the development of HMBD-501 as a promising candidate in the treatment of HER3 expressing solid tumors.
DOI:
https://doi.org/10.1158/1538-7445.AM2023-2660
